Small Businesses

Pfizer, Moderna CEOs predict a return to “normal life” in a year

  • 2 min Read
  • September 28, 2021

Author

Escalon Editorial Team

Table of Contents

Pfizer CEO and Chairman Albert Bourla said he anticipates a global return to regular pre-pandemic life by the end of 2022.  “Within a year I think we will be able to come back to normal life,” Bourla stated in a recent interview on ABC News

Bourla added that this does not mean variants of the coronavirus will cease to exist or that COVID-19 vaccines will become unnecessary. The most likely scenario is that “normalcy” will include the emergence of new variants of the virus. That means annual revaccinations as booster shots are almost certainly going to be a part of the landscape. 

But for a clearer picture, Bourla advises taking a wait-and-see approach based on newer data as it becomes available.

Bourla’s sentiment echoed by Moderna CEO

Stephane Bancel, the CEO of Moderna, also expects normal life will resume by next year, assuming COVID-19 vaccine production increases to ensure a sufficient global supply.

“If you look at the industry-wide expansion of production capacities over the past six months, enough doses should be available by the middle of next year so that everyone on this earth can be vaccinated,” Bancel said in an interview, Reuters reported. “Boosters should also be possible to the extent required.”

Like Bourla, Bancel emphasized that annual coronavirus vaccine booster shots will also “undoubtedly” be required after the pandemic is contained.

CDC approves, WHO opposes

Bourla’s and Bancel’s comments followed the U.S. Food and Drug Administration’s decision to recommend the third dose of COVID-19 booster shots of Pfizer’s vaccine for certain populations.

On Sept. 24, the Centers for Disease Control and Prevention authorized the distribution of the Pfizer-BioNTech COVID-19 Vaccine to older Americans and adults with underlying medical conditions. And in an unusual decision, CDC Director Dr. Rochelle Walensky overruled an advisory panel and approved the boosters for U.S workers in high-risk occupational and institutional settings. 

Meanwhile, citing the importance of equitable vaccine distribution, the World Health Organization continues to strongly oppose the widespread rollout of booster shots.

Talk to our team today to learn how Escalon can help take your company to the next level.

  • Expertise you can trust

    Our team is made up of seasoned professionals who bring years of industry experience to the table. You gain a trusted advisor who understands your business inside out.

  • Quality and consistency

    Say goodbye to the hassles of hiring, training and managing in-house finance teams. You will never have to worry about unexpected leave of absence or retraining new employees.

  • Scalability and Flexibility

    Whether you’re a small business or a global powerhouse, our solutions scale with your needs. We eliminate inefficiencies, reduce costs and help you focus on growing your business.

Contact Us Today!

Tap into the latest insights from experts in your industry

Financial Operations

Stock-Based Compensation Expense: How to Record It Correctly

Stock-based compensation is one of the largest non-cash expenses on most startup income statements and one of the most consistently...

HR & People Operations

Global Payroll: How to Pay a Distributed Team Compliantly

A company with 15 employees in 9 countries used to be unusual. In 2026, it is a normal Series A....

Tax Operations

QSBS Tax Exemption: How Founders & Early Employees Save on Taxes

QSBS is one of the most valuable and most overlooked tax provisions in the US tax code. A founder who...

Financial Operations

ASC 606 Revenue Recognition for SaaS: A Practical Guide

Every SaaS finance team has had the same argument at some point: when do we actually recognize this revenue? A...

Financial Operations

Web3 Accounting: How Token & Crypto Treasuries Change the Books

A Web3 company’s books look familiar at the top level: revenue, expenses, payroll, cash. The complexity starts where the cash...

Financial Operations

Cash Runway: How to Calculate It and Extend It

Cash runway is the simplest and most consequential metric in startup finance. It is the answer to one question: how...

Financial Operations

Nonprofit Accounting Basics: Fund Accounting vs Standard Books

Nonprofit accounting looks similar to business accounting on the surface but answers an entirely different question. A business asks: are...

Financial Operations

SaaS Rule of 40 Explained: How Investors Read Your Numbers

Growth or profitability? For most SaaS founders, the answer used to be growth at all costs. That changed when capital...

Financial Operations

ARR vs MRR: What Each Metric Tells You and When to Use It

Every SaaS founder has been asked the same question by an investor: what is your ARR? And almost every founder...